Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm Metastasis 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 29blinatumomab 19Vincristine 16Specimen Handling 13Methotrexate 13Dexamethasone 13fludarabine 12Prednisone 11Cytarabine 11Biopsy 11Doxorubicin 9Asparaginase 9Rituximab 8Mercaptopurine 8Inotuzumab Ozogamicin 8merphos 7Spinal Puncture 7N,N-dicyclohexyl-isoborneol-10-sulfonamide 7Magnetic Resonance Spectroscopy 7venetoclax 6prednylidene 6dexamethasone acetate 6dexamethasone 21-phosphate 6deltacortene 6azathiopurine 6auricularum 6Etoposide 6Daunorubicin 6Calcium Dobesilate 6pegaspargase 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Burkitt Lymphoma × CX 5461 × Clear all
NCT07069699 2026-05-13

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

National Cancer Institute (NCI)

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡